Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DTPA-Nb2F8
- Development stage
- Preclinical
- Lead developer
- Centre Hospitalier Universitaire de Liège
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-DTPA-Nb2F8 is a radiolabeled single-domain antibody (nanobody) conjugate being developed for the treatment of CD38-expressing malignancies, primarily multiple myeloma. The agent consists of the anti-CD38 nanobody clone 2F8 conjugated via the chelator diethylenetriaminepentaacetic acid (DTPA) to the beta-emitting radioisotope lutetium-177 (177Lu). By targeting CD38, which is highly expressed on multiple myeloma cells, the nanobody delivers targeted radiation directly to the tumor site, inducing DNA damage and cell death while minimizing systemic toxicity. Preclinical studies in mouse xenograft models of multiple myeloma have demonstrated specific tumor targeting, rapid clearance from non-target tissues, and dose-dependent tumor regression and survival prolongation.
- Other names
- 177Lu-labeled anti-CD38 nanobody 2F8177Lu-labeled anti-CD38 sdAb 2F8177Lu-labeled nanobody 2F8lutetium-177-labeled anti-CD38 nanobody 2F8lutetium177-labeled anti-CD38 nanobody 2F8lutetium 177-labeled anti-CD38 nanobody 2F8lutetium-177-labeled anti-CD38 sdAb 2F8lutetium177-labeled anti-CD38 sdAb 2F8lutetium 177-labeled anti-CD38 sdAb 2F8
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on 177Lu-DTPA-Nb2F8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DTPA-Nb2F8.